Mapping the Brain While on Psychedelics with Manesh Girn
Psychedelic neuroscientist Manesh Girn talks about his research into neuroimaging of the brain while subjected to psychedelic states and more.
Similar Posts
![MindMed Stock Price Targets [How HIGH can $MMED / $MMEDF Go?]🚀](https://psychedelicspotlight.com/wp-content/uploads/2022/06/maxresdefault-44-600x338.jpeg)
MindMed Stock Price Targets [How HIGH can $MMED / $MMEDF Go?]🚀
Today we are going to discuss my 5 year price targets for MindMed, MMEDF on the American OTC market, MMED on the Canadian Neo market and MMQ on the European Frankfurt Stock exchange.
Piggy backing off of a decades worth of positive research showing that substances like LSD, Ibogaine, psilocybin and MDMA can treat mental health illnesses better than current methods by an order of magnitude, MindMed is in my opinion by far the most advanced psychedelic medicines company that retail investors can buy on the public markets which is why MindMedicine is one of my top psychedelic stocks in 2021.
In this video, we’re going to look at 4 different 5 year price targets for MindMed, and assign them a level of probability. The four cases will be:
1. The 5 year bear case for MindMed’s stock
2. The Neutral case for MindMed LT
3. The bull case price target for MindMed
4. The Super Bull case
Timestamps:
0:00 – Intro
2:54 – The Bear Case for MindMed
5:37 – The Neutral Case/ MindMed’s Stagnation
7:49 – The Bull Case for MMED/MMEDF Stock
10:18 – The Super Bull Case for MindMed
13:08 – Note of Caution Plus Answer to Meor’s Nasdaq question
Just as a brief note, in this video we are going to be using MMEDF, and all figures will be in American dollars
And because this is all going to be speculation, the entirety of the episode will take place in, The Speculation Zone
I hope you guys found some value in this and I’ll keep you posted for more changes!
Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
Follow us on social media! 🙌
Instagram: @psychedelicinvestor
Email: thepsychedelicinvestor@gmail.com
Facebook: @thepsychedelicinvestor
Music: www.bensound.com
https://benzinga.grsm.io/jameshallifax1834
https://benzinga.grsm.io/thepsychedelicinvestor
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
#MindMed #MindmedStock #MMEDNews
We NEED to Talk about the Compass Pathways Psilocybin-for-Depression Trial Results: A WIN for CMPS??
In today’s episode, we discuss the results of the much awaited phase 2b clinical trial using psilocybin (comp360) to treat treatment-resistant-depression. This Compass Pathways (Nasdaq: CMPS) trial is so important for a couple of reasons: first, it is the largest ever psychedelics clinical trial, with 219 people completing the trial; and second because it is the furthest progressed psilocybin trial ever, being in phase 2b.
So what did the results say? Can Magic Mushrooms treat depression? Can Psychedelics help Mental Health?
Well, the results are mixed. About a quarter of the people who underwent Compass Pathways psychedelic therapy program, who received 25 mg of psilocybin (Comp 360), entered remission after 12 weeks. And almost a third of individuals in this group saw their depression symptoms decrease by 50% or more, as measured by the MADRS scale. This is more than double the success rate for the control group, showing strong significant effects of psilocybin therapy on depression. Therefore, it is clear that psychedelics like psilocybin CAN help mental health… at least somewhat
However, many, myself included, were hoping for stronger results, such as the MDMA to treat PTSD phase 3 results that MAPS released earlier this year. This led to disappointment at the positive results, as they were not as game changing as we had hoped.
In this episode, we describe Compass Pathways’ psilocybin for depression clinical trial, explain the results, and then try to put said results into context. We finish by looking towards the future, and discussing where Compass Pathways, and other psychedelic medicines companies like MindMed, Cybin and Small Pharma, should go from here.
Enjoy the episode!
Follow us on social media!
Instagram: @thepsychedelicinvestor
Facebook: @thepsychedelicinvestor
James’ Twitter: @Psy_Invest
Maria’s Twitter (Producer & Editor): @Psy_Holy
Want to collaborate? Send us an email at:
thepsychedelicinvestor@gmail.com
Music from:
www.bensound.com
Video editing: @themyaholy
Links:
Compass Results: https://ir.compasspathways.com/static-files/0f9fbce8-2619-438b-a6ba-5bbe2ba08cf6
Montgomery-Asberg Depression Rating Scale (MADRS):
https://en.wikipedia.org/wiki/Montgomerysberg_Depression_Rating_Scale
MAPS MDMA-PTSD Study:
https://www.nytimes.com/2021/05/03/health/mdma-approval.html
Comp 360 Open Label Study:
https://www.globenewswire.com/en/news-release/2021/10/20/2317456/0/en/Open-label-study-of-COMP360-psilocybin-therapy-for-depression-in-cancer-patients-demonstrates-feasibility-of-simultaneous-psilocybin-administration-in-small-groups.html
MindMed Psilocybin SSRI Study:
https://mindmed.co/news/press-release/mindmed-and-liechti-lab-provide-results-from-their-psilocybin-rd-collaboration/
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.
#CompassPathways #psilocybin #depression
MindMed’s Patent STRATEGY & WHY Haven’t We Covered It YET? (MMED/ MNMD)
MindMed’s Patent STRATEGY & WHY Haven’t We Covered It YET? (MMED/ MNMD)
Patents and IP are important because it allows companies to protect their innovations and re-coup sunk costs into research and development by giving them a set period of time that only they can profit from any inventions they developed.
Given the importance of patents, some people have reached out and have asked why I haven’t talked about MindMed’ patents more.
For example, if you go to their Investors deck, you will see that MindMed, (MMED: NEO), (MNMD : NASDAQ), has 45+ different patent applications. We definitely haven’t done 45 videos on the matter. And that is because we actually don’t know what most of these patent applications are!
Enjoy the episode!
Follow us on social media! 🙌
Instagram: @thepsychedelicinvestor
Facebook: @thepsychedelicinvestor
Want to collaborate? Send us an email at:
thepsychedelicinvestor@gmail.com
Music from:
www.bensound.com
Video editing: @themyaholy
Check out our Benziga discounts
https://benzinga.grsm.io/jameshallifax1834
https://benzinga.grsm.io/thepsychedelicinvestor
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.
#mindmed #mmed #mnmdstock
Interview with Bright Minds Biosciences’ CEO Ian McDonald
In today’s episode of the Psychedelic Spotlight podcast, the Psychedelic…
Creating Inclusive KAP Training Practices with TRIPP Founder Jennifer Montjoy
In this episode, Swati Sharma sits down with Jennifer Montjoy, Founder of Transpersonal Research Institute of Psychotherapeutic Psychedelics also known as TRIPP.
![Is it TOO LATE to buy MindMed? [MMEDF] 🍄](https://psychedelicspotlight.com/wp-content/uploads/2022/06/maxresdefault-151-600x338.jpeg)
Is it TOO LATE to buy MindMed? [MMEDF] 🍄
MindMed (MMEDF/MMED) stock EXPLODED in the past week which raises the question: Is it too late to BUY MindMed stock? Watch the video as I provide my insight on some factors you might want to consider. 💯
Music: www.bensound.com
Instagram: @psychedelicinvestor
Facebook: @thepsychedelicinvestor
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.